Document is current
Any future updates will be listed below
-
Authors
Sutton, Thomas L.
Walker, Brett S.
Billingsley, Kevin G.
Corless, Christopher L.
Sheppard, Brett C.
Heinrich, Michael C.
Mayo, Skye C.
- License Information
-
More Information
Article History
First Online: 29 July 2022
Acknowledgement
: M.C.H. received partial salary support from the following sources: a research grant from the Jonathan David Foundation, a VA Merit Review grant (I01BX005358), and a NCI R21 grant (R21CA263400).
: Dr. Michael Heinrich receives consulting fees from Novartis, Deciphera Pharmaceuticals, Blueprint Medicines, and Theseus Pharmaceuticals. Dr. Michael Heinrich holds multiple patents on the diagnosis and/or treatment of gastrointestinal stromal tumor (GIST). One patent on treatment of GIST has been licensed by the Oregon Health and Science University (OHSU) to Novartis.
Free to read: This content has been made available to all.
